Mobile Navigation

Chemical Engineering

View Comments

Thermo Fisher opens new biomanufacturing facility in Chelmsford, Mass.

| By Mary Bailey

Thermo Fisher Scientific Inc. (Waltham, Mass.) opened a new biomanufacturing facility in Chelmsford, Massachusetts. The $160 million, 85,000-square-foot facility will help meet growing demand for the biologic materials needed to produce vaccines and breakthrough therapies for cancer and other diseases. This new site is part of Thermo Fisher’s $650 million multi-year investment to expand its bioprocessing production capabilities.

The technologies produced at the Chelmsford site are used in the purification process of developing biotherapeutics and vaccines. These products help save time and reduce costs so that new treatments can reach more patients faster. With the opening of the site in Chelmsford, Thermo Fisher continues to bring its capacity investments online to support customers as they grow and scale.

“This market continues to grow and the world’s leading biopharmaceutical companies depend on our technologies, services and expertise to help deliver life changing therapies to patients,” said Jean Luo, vice president and general manager, purification and pharma analytics, Thermo Fisher Scientific. “The Chelmsford site will help us provide our customers with the critical resin materials they need as they scale up production and bring new innovations to market. This ultimately helps ensure more patients get the treatments they need faster.”

When fully staffed, the Chelmsford site will employ up to 250 people in roles across manufacturing, engineering, procurement, quality, warehousing, site leadership and more.